Alkermes plc. Disposal Group, Including Discontinued Operation, Operating Expense
Alkermes plc. (ALKS) reported Disposal Group, Including Discontinued Operation, Operating Expense of $5.79 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense · last filed 2026-02-25
- Alkermes plc. disposal group, including discontinued operation, operating expense for the quarter ending 2024-12-31 was -$1.12M, a 102.74% decline year-over-year.
- Alkermes plc. disposal group, including discontinued operation, operating expense for the quarter ending 2024-09-30 was $481.00K, a 98.94% decline year-over-year.
- Alkermes plc. disposal group, including discontinued operation, operating expense for the quarter ending 2024-06-30 was $3.91M, a 90.70% decline year-over-year.
- Alkermes plc. disposal group, including discontinued operation, operating expense for the quarter ending 2024-03-31 was $2.52M, a 93.11% decline year-over-year.
- Alkermes plc. disposal group, including discontinued operation, operating expense for fiscal 2024 was $5.79M, a 96.49% decline from fiscal 2023.
- Alkermes plc. disposal group, including discontinued operation, operating expense for fiscal 2023 was $164.80M, a 21.02% increase from fiscal 2022.
- Alkermes plc. disposal group, including discontinued operation, operating expense for fiscal 2022 was $136.18M, a 7.20% increase from fiscal 2021.
- Alkermes plc. disposal group, including discontinued operation, operating expense for fiscal 2021 was $127.03M.
| Period end | Disposal Group, Including Discontinued Operation, Operating Expense 3 month | Disposal Group, Including Discontinued Operation, Operating Expense 6 month | Disposal Group, Including Discontinued Operation, Operating Expense 9 month | Disposal Group, Including Discontinued Operation, Operating Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | -$1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$639.00K derived: sum of 2 quarters · filed 2026-02-25 | $3.27M derived: sum of 3 quarters · filed 2026-02-25 | $5.79M 10-K · filed 2026-02-25 |
| 2024-09-30 | $481.00K 10-Q · filed 2025-10-28 | $4.39M derived: sum of 2 quarters · filed 2025-10-28 | $6.91M 10-Q · filed 2025-10-28 | $47.77M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $3.91M 10-Q · filed 2025-07-29 | $6.43M 10-Q · filed 2025-07-29 | $47.29M derived: sum of 3 quarters · filed 2026-02-25 | $92.63M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $2.52M 10-Q · filed 2025-05-01 | $43.38M derived: sum of 2 quarters · filed 2026-02-25 | $88.72M derived: sum of 3 quarters · filed 2026-02-25 | $130.80M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $40.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $86.20M derived: sum of 2 quarters · filed 2026-02-25 | $128.28M derived: sum of 3 quarters · filed 2026-02-25 | $164.80M 10-K · filed 2026-02-25 |
| 2023-09-30 | $45.35M 10-Q · filed 2024-10-24 | $87.42M derived: sum of 2 quarters · filed 2024-10-24 | $123.94M 10-Q · filed 2024-10-24 | |
| 2023-06-30 | $42.08M 10-Q · filed 2024-07-24 | $78.60M 10-Q · filed 2024-07-24 | ||
| 2023-03-31 | $36.52M 10-Q · filed 2024-05-01 | |||
| 2022-12-31 | $136.18M 10-K · filed 2025-02-12 | |||
| 2021-12-31 | $127.03M 10-K · filed 2024-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |